A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer

Anti-PD1 immunotherapy has emerged as a gold-standard treatment for first- or second-line treatment of stage IV NSCLC, with response rates ranging from 10 to 60%. Strategies to improve the disease control rate are needed. Several reports suggested that debulking surgery enhances anti-tumor immunity....

Descripción completa

Detalles Bibliográficos
Autores principales: Guisier, Florian, Cousse, Stephanie, Jeanvoine, Mathilde, Thiberville, Luc, Salaun, Mathieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858444/
https://www.ncbi.nlm.nih.gov/pubmed/31729430
http://dx.doi.org/10.1038/s41598-019-52913-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858444/
https://www.ncbi.nlm.nih.gov/pubmed/31729430
http://dx.doi.org/10.1038/s41598-019-52913-z

Ejemplares similares